Aiforia builds a deep learning AI platform that analyzes ultra-high-resolution biopsy images to assist pathologists in identifying cancer cells more quickly and precisely. The company has created thousands of AI models for research and provides CE-IVD marked AI solutions used in healthcare and research environments in Europe and worldwide. Aiforia positions its technology to improve diagnostic capabilities, support medical research, and enable earlier and more accurate disease detection. The company plans to continue developing new and existing AI-powered image analysis solutions and to expand its commercial presence internationally. Financially, Aiforia recently secured €20 million in venture debt from the European Investment Bank, structured in tranches with milestone-based access and a synthetic warrant arrangement.

Total raised

$60M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Aug 2026